Design win with Israel-based drone manufacturer for ISR Platform slated for deployment in India Accelerates Mobilicom’s commercial footprint in the high-growth APAC region Palo Alto, California, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB, MOBBW) (“Mobilicom” or the “Company”), a provider of cybersecurity and robust solutions for drones and robotics, today announced it has secured a design win with a new customer and initial order from a prominent Israel-based drone manufacturer, which ...

Core Viewpoint - Syndax Pharmaceuticals will report its fourth quarter and full year 2025 financial results on February 26, 2026, and will host a conference call and live audio webcast to discuss the results and provide a business update [1]. Group 1: Financial Results Announcement - The earnings release is scheduled for Thursday, February 26, 2026 [1]. - A conference call and live audio webcast will take place at 4:30 p.m. ET on the same day [1]. Group 2: Access Information - The live audio webcast and accompanying slides can be accessed through the Events & Presentations page in the Investors section of the Company's website [2]. - Conference ID for the call is Syndax4Q25, with domestic dial-in number 800-590-8290 and international dial-in number 240-690-8800 [2]. - A replay of the conference call will be available approximately 24 hours after the event and will remain accessible for 90 days [2]. Group 3: Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [3]. - Key products in the pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody targeting the CSF-1 receptor [3]. - The company is committed to advancing cancer care and is conducting several clinical trials across various treatment stages [3].

Core Insights - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies through PLK1 inhibition [3] - The company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, with a live webcast available for interested parties [1][2] Company Overview - Cardiff Oncology is advancing innovative cancer treatments, particularly targeting PLK1 inhibition, which is recognized as a validated oncology target with significant potential to change clinical practice [3] - The lead asset, onvansertib, is an oral PLK1 inhibitor currently in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large patient population with high unmet needs [3] - Onvansertib is also being investigated in other PLK1-driven cancers through ongoing investigator-initiated trials and has demonstrated robust clinical activity as a single agent in challenging tumors [3]

Core Insights - InterCure reports preliminary estimated revenue of NIS 265 million for 2025, marking an 11% increase compared to 2024, with nearly 20% revenue growth in the second half of 2025 [1][5] - The company achieved its twelfth consecutive half-year of positive Adjusted EBITDA, indicating consistent financial performance [1][5] - Significant revenues were generated from the German market during the second half of 2025, highlighting successful market expansion efforts [1][4] Financial Highlights - Estimated annual revenue for 2025 is NIS 265 million, with approximately NIS 135 million generated in the second half [5] - Positive Adjusted EBITDA is expected in both halves of 2025, continuing the trend of financial stability [5] - Cash on hand as of December 31, 2025, is reported at NIS 43 million [5] Strategic Developments - The company resumed production, importation, and sales from the Nir Oz facility after disruptions due to the October 2023 attack [5] - InterCure launched over 70 new GMP SKUs in 2025, establishing category-leading positions in premium medical products [5] - A strategic acquisition of Botanico Ltd. is anticipated to enhance access to premium U.S. genetics and cultivation technologies, with expected revenues of over NIS 30 million in the second half of 2026 [5] - A partnership with Cannasoul R&D Ltd. was established, acquiring a 28% stake with an option to increase to 51%, enhancing research and pharmaceutical capabilities [5] Regulatory and Market Position - The company is closely monitoring regulatory developments in the U.S. regarding cannabis regulations, positioning itself to benefit from evolving market conditions [5] - InterCure's vertically integrated model and international partnerships are expected to drive long-term value for patients and shareholders [4][5]

Core Viewpoint - Sprott Inc. reported significant growth in Assets Under Management (AUM) and net income for the year ended December 31, 2025, driven by market value appreciation and strong demand for precious metals and critical materials [2][11][20]. AUM Highlights - AUM reached $59.6 billion as of December 31, 2025, representing a 21% increase from $49.1 billion as of September 30, 2025, and an 89% increase from $31.5 billion as of December 31, 2024 [2][3]. - The growth in AUM was attributed to market value appreciation across fund products and $3.9 billion in net sales, particularly in the Exchange Listed Products segment [2][3]. Revenue Highlights - Management fees for the quarter were $63.8 million, up 54% from $41.4 million for the same quarter in 2024, and $199 million for the full year, up 28% from $155.3 million in 2024 [6]. - Carried interest and performance fees for the quarter were $38.1 million, a significant increase from $2.5 million in the same quarter of 2024, and $54.7 million for the full year, up from $7.3 million in 2024 [6]. - Total net revenues for the year were $285.1 million, compared to $178.7 million in 2024, reflecting strong performance across various segments [20]. Expense Highlights - Net compensation expense for the quarter was $20.9 million, up 22% from $17 million in the same quarter of 2024, and $75.1 million for the full year, up 12% from $66.8 million in 2024 [5]. - Stock-based compensation expense for the quarter was $28.2 million, significantly higher than $5 million in the same quarter of 2024, due to a transition to a cash-settled stock-based compensation plan [5][21]. - SG&A expenses were $5.1 million for the quarter, a slight increase from $4.9 million in the same quarter of 2024, while full-year SG&A expenses decreased to $18.5 million from $18.8 million in 2024 [7]. Earnings Summary - Net income for the quarter was $28.7 million ($1.11 per share), up from $11.7 million ($0.46 per share) in the same quarter of 2024, and $67.3 million ($2.61 per share) for the full year, up 37% from $49.3 million ($1.94 per share) in 2024 [11][22]. - Adjusted EBITDA for the quarter was $42.1 million ($1.63 per share), an 88% increase from $22.4 million ($0.88 per share) in the same quarter of 2024, and $121.4 million ($4.71 per share) for the full year, up 43% from $85.2 million ($3.35 per share) in 2024 [11][24]. Subsequent Events - As of February 13, 2026, AUM increased to $70.1 billion, reflecting an 18% rise from $59.6 billion as of December 31, 2025, driven by $7.7 billion in market value appreciation and $2.8 billion in net inflows [11]. - The Board of Directors announced a quarterly dividend of $0.40 per share on February 18, 2026 [11].

MONTREAL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; “BRW” or the “Company”) is pleased to announce it has identified three new high priority lithium targets (area A, B and C in Figure 1) at the Anatacau Main Project, where drilling is currently underway, located in the Eeyou-Istchee James Bay region of Quebec. The Project is strategically situated 22 kilometers east and along strike of a major proven lithium-bearing structural corridor also hostin ...

ROUYN-NORANDA, Quebec, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) (OTCQB : ABMBF) announces its financial results for the second quarter ended December 31, 2025. All monetary values ​in this press release are expressed in Canadian dollars, unless otherwise indicated. Financial statements and management discussion and analysis are available on SEDAR+. Summary of financial results (In dollars)Three months ended December 31,Six months ended Decembe ...

Core Viewpoint - Labrador Gold Corp. warns shareholders against the promises made by Coloured Ties Capital Inc., stating that these are designed to influence proxy voting rather than create long-term value [1][3][6]. Group 1: Shareholder Communication - The Board of Directors recommends that shareholders vote exclusively on the BLUE Proxy and against the Dissident's resolutions [2]. - LabGold emphasizes the importance of facts and safeguards for shareholders, criticizing the Dissident's conditional dividend pledge as a desperate measure [3]. - The Board has previously communicated to shareholders that the Dissident is repeating past tactics that have proven misleading [6]. Group 2: Historical Context - The Dissident, led by Kal Malhi, previously made similar promises during a campaign against GrowMax Resources Inc., which resulted in a significant cut in promised dividends [4][7]. - Following the Dissident's campaign at GrowMax, shareholders experienced a trading halt, share consolidation, and a redirection of capital that negatively impacted their investments [7]. Group 3: Financial Position of the Dissident - Coloured Ties' financial statements indicate minimal cash reserves, with only CAD $658,000 available as of September 30, 2025, suggesting a motive to target LabGold's treasury [8]. - The Dissident's history of broken promises and misleading information has left shareholders worse off in previous campaigns [8]. Group 4: Recommendations from Experts - Independent proxy advisors ISS and Glass Lewis recommend that shareholders vote only on the BLUE Proxy, stating that the Dissident has not presented a compelling case for change [10]. - LabGold's strategy is presented as a transparent and regulated approach aimed at long-term value creation for all shareholders, contrasting with the Dissident's short-term inducements [14].

Core Insights - Codere Online has launched a new iOS Poker application in Mexico, aiming to enhance its online gaming product offerings and meet customer demand [1][5] - The iOS Poker app is developed in partnership with Playtech, integrating with their player-vs-player (P2P) Poker network, which enhances user experience through real-time competition and increased liquidity [2][6] - The company has observed strong demand for Poker in Mexico, with over 1,300 unique active users per month, indicating the product's relevance and growth potential [4] Product Development - The new iOS Poker app features a stable interface, cash tables, multi-table tournaments, Sit & Go formats, and fast-paced modes, while also incorporating responsible gaming tools [5][6] - The launch of the Poker app is part of Codere Online's strategy to broaden its product offerings and improve user experience across key gaming verticals [6] Market Position - Codere Online operates in several core markets including Spain, Mexico, Colombia, Panama, and Argentina, leveraging its physical presence in Latin America to support its online business [8] - The partnership with Playtech allows Codere Online to provide access to one of the most competitive poker networks in the industry, enhancing its market position [6]

VANCOUVER, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- VR Resources Limited (“VR” or the “Company”, TSXV: VRR) is pleased to announce that it has submitted its application for a Notice of Intent (“NOI”) drill permit to the Nevada Bureau of Land Management (the “BLM”) for its New Boston moly-tungsten-copper-silver porphyry project in Nevada. The Company applied for, and received a similar NOI permit from the BLM for its drilling on the East Zone target at New Boston in 2024 within 15 business days, ...